Revolution Medicines Inc (OQ:RVMD)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 700 Saginaw Dr
REDWOOD CITY CA 94063-4752
Tel: N/A
IR: See website
Key People
Mark A. Goldsmith
Founding President, Chief Executive Officer, Board Director
Martin William Burke
Founder, Scientific Advisory Board Chairman
Margaret A. Horn
Chief Operating Officer
Jack Anders
Vice President - Finance and Principal Accounting Officer
Adrian Gill
Vice President - Chemistry & CMC
Business Overview
Revolution Medicines, Inc. is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company's pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the Company is developing a portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and son of sevenless homolog one (SOS1), as well as RMC-5552. RMC-5552 is a selective inhibitor of mammalian target of rapamycin complex one (mTORC1) that is designed to preserve the tumor suppressive activity.
Financial Overview
For the nine months ended 30 September 2019, Revolution Medicines Inc revenues increased from $9.8M to $38M. Net loss applicable to common stockholders increased 23% to $43.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 95% to $63.3M (expense).
Employees: 90 as of Sep 30, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $1,487M as of Sep 30, 2019
Annual revenue (TTM): $48.30M as of Sep 30, 2019
EBITDA (TTM): -$43.06M as of Sep 30, 2019
Net annual income (TTM): -$56.91M as of Sep 30, 2019
Free cash flow (TTM): -$52.04M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 59,002,309 as of Feb 13, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization